Denali Therapeutics Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: ELECTION OF DIRECTORS: David Schenkein, M.D.

Denali Therapeutics Inc.’s own tally for this item (“Elect Director: David Schenkein, M.D.”): 91,814,688 for, 33,030,600 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class III director, to hold office until the Company's 2029 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 37,281,142 for, 10,478,120 withheld, 311,495 abstained.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: ELECTION OF DIRECTORS: Jennifer Cook

Denali Therapeutics Inc.’s own tally for this item (“Elect Director: Jennifer Cook”): 75,998,259 for, 48,847,029 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class III director, to hold office until the Company's 2029 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 61% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 28,911,364 for, 13,528,808 withheld, 5,630,585 abstained.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: ELECTION OF DIRECTORS: Ryan Watts, Ph.D.

Denali Therapeutics Inc.’s own tally for this item (“Elect Director: Ryan Watts, Ph.D.”): 121,220,572 for, 3,624,716 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class III director, to hold office until the Company's 2029 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 47,151,247 for, 844,207 withheld, 75,304 abstained.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, executive compensation.

Denali Therapeutics Inc.’s own tally for this item (“3. Advisory Vote to Approve Executive Compensation”): 117,038,745 for, 7,088,810 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Advisory Vote to Approve Executive Compensation The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 70 managers: 44,679,372 for, 3,347,906 against, 43,827 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 222 managers: 74,897,630 for, 6,063,611 against, 81 abstained, 3,322 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2026.

Denali Therapeutics Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, ”): 137,516,267 for, 420,305 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting:”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 71 asset managers below reported 48,009,137 for, 18,153 against, 43,825 abstained.

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.